pyctx.com | ACN 098 391 961 1 29 July 2026 Q2 2026 SHAREHOLDER UPDATE • PYC is a biotechnology company developing a pipeline of precision medicines designed to change the lives of patients who have genetic diseases and no treatment options available today • The Company...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- PKD - Safety Committee Approves Dose Escalation
- ADOA Program Update
- PKD - Initiation of Multiple Dose Clinical Trial
- Presentation of Ophthalmology Clinical Trial Data at ARVO
- ADOA Program - SRC Approve Progression to Multi-Dose Study
Later from PYC Therapeutics
- Notification regarding unquoted securities - PYC
- Change of Director's Interest Notice
- Investor Webinar
- Appendix 4E
- 2026 Annual Report to Shareholders
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics